This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aratana Therapeutics Strengthens Executive Management Team To Support Growth And Commercialization Initiatives

KANSAS CITY, Kan. and BOSTON, Nov. 11, 2013 /PRNewswire/ --  Aratana Therapeutics, Inc . (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has appointed Craig Tooman to the position of Chief Financial Officer and named John C. Ayres as its General Counsel.  Louise Mawhinney, former CFO of Aratana, will remain with the company.

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics stated, "Aratana has grown considerably over the past year, having successfully completed our initial public offering in June and now, with the acquisition of Vet Therapeutics, becoming a commercial company.  The appointments of Craig Tooman and John Ayres, both highly experienced commercial biopharmaceutical executives, will substantially enhance our strategy to establish Aratana as the industry leader in pet therapeutics. I'm extremely pleased to welcome Craig and John to our executive team and look forward to benefitting from their depth of knowledge and strategic vision."

A seasoned pharmaceutical executive with more than 20 years of industry experience, Mr. Tooman is widely versed in international finance, sales, market research, business intelligence, corporate strategy, M&A and investor relations.  Immediately prior to his joining the executive team, Mr. Tooman had served as a Director and Chairman of Aratana's Audit Committee; he served as a member of the Board of Directors from March 2012 until his appointment as Chief Financial Officer.  Mr. Tooman will also transition from his current position of CEO of Avanzar Medical, Inc., an oncology company, to focus on Aratana.

Previously, Mr. Tooman held executive positions at large pharmaceutical companies, including Pharmacia and Upjohn, and served as the CFO of Enzon Pharmaceuticals and Ikaria.  While at ILEX Oncology, Mr. Tooman was a member of the executive team and was instrumental in transitioning the company from a CRO into a proprietary business responsible for developing successful oncology products. This strategic transformation ultimately led to ILEX being sold to Genzyme Corporation for $1.1 billion

Mr. Ayres joins Aratana from Amgen Inc. where he served as a member of the Corporate and Securities Law group for the world's largest independent biotechnology company.  Within Amgen, Mr. Ayres advised the company's finance, human resources, investor relations and corporate communications groups.  Prior to Amgen, Mr. Ayres was an associate at Latham & Watkins LLP where he specialized in public company counsel, including SEC compliance, initial public and follow-on stock offerings and mergers and acquisitions.   

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs